Welcome to CSNpharm! For Research Use Only!
Androgen Receptor
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN12743 | RU 58841 | 154992-24-2 | RU 58841 is a nonsteroidal antiandrogen for potential use as a topical treatment for androgen-dependent conditions including acne, pattern hair loss, and excessive hair growth. |
| CSN19838 | RD162 | 915087-27-3 | RD 162 is an orally active and very potent antagonist of androgen receptor AR and is a second-generation of antiandrogen for the treatment of advanced prostate cancer and highly recommended tool in AR research |
| CSN17663 | ORM-15341 | 1297537-33-7 | ORM-15341 is a potent and full antagonist for human AR hAR with IC50 values of 38 nM as shown by transactivation assays in AR-HEK293 cells stably expressing full-length hAR and an androgen-responsive luciferase reporter gene construct |
| CSN17664 | Darolutamide | 1297538-32-9 | ODM-201 is a competitive inhibitor of androgen receptor with IC50 value of 26 nM and inhibits AR nuclear translocation with Ki value of 11 nM. |
| CSN16774 | Nilutamide | 63612-50-0 | Nilutamide is a non-steroidal androgen receptor antagonist and also inhibits androgen biosynthesis in vitro |
| CSN17614 | N-desmethyl Enzalutamide | 1242137-16-1 | N-Desmethyl enzalutamide is a major metabolite of Enzalutamide Enzalutamide MDV3100 is an androgen-receptor AR antagonist with IC50 of 36 nM |
| CSN18667 | GSK-2881078 | 1539314-06-1 | GSK 2881078 is a selective androgen receptor modulator potentially for the treatment of cachexia |
| CSN17573 | GLPG0492 (R enantiomer) | 1215085-93-0 | GLPG0492 R-enantiomer is the R-Enantiomer of GLPG-0492 which is a selective androgen receptor modulator |
| CSN17572 | GLPG0492 | 1215085-92-9 | GLPG0492 is a selective androgen receptor modulator and exhibits anabolic activity on muscle strongly dissociated from the androgenic activity on prostate after oral dosing |
| CSN16707 | Flutamide | 13311-84-7 | Flutamide is a competitive non-steroidal antagonist of androgen receptor. |
| CSN10468 | EPI-001 | 227947-06-0 | EPI-001 is an androgen receptor N-terminal domain antagonist with IC50 of 6 M and a selective PPAR-gamma modulator |
| CSN12389 | Enzalutamide | 915087-33-1 | Enzalutamide is an androgen-receptor AR antagonist with IC50 of 36 nM in LNCaP cells |
| CSN16582 | BMS-564929 | 627530-84-1 | BMS-564929 is an androgen receptor AR agonist binds to androgen receptor AR with a Ki of 211016 nM |
| CSN12437 | Bicalutamide | 90357-06-5 | Bicalutamide is non-steroidal androgen receptor antagonist with IC50 value of 190 nM |
| CSN17150 | AZD3514 | 1240299-33-5 | AZD3514 is a potent and oral androgen receptor downregulator with Ki of 22 M and has ability of reducing AR protein expression |
| CSN17338 | Dimethylcurcumin | 52328-98-0 | ASC-J9 an antitumor agent suppresses castration-resistant prostate cancer growth via degradation of full-length and splice variant androgen receptors |
| CSN28405 | Bavdegalutamide | 2222112-77-6 | ARV-110 is an orally active, specific androgen receptor PROTAC degrader with DC50 < 1nM. |
| CSN13830 | Apalutamide | 956104-40-8 | ARN-509 can compeitively and selectively inhibit androgen receptor with IC50 value of 16 nM |
| CSN28523 | ARD-69 | 2316837-10-0 | ARD-69 is a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. ARD-69 induces degradation of AR protein in AR-positive prostate cancer cell lines in a dose- and time-dependent manner. ARD-69 achieves DC50 values of 0.86, 0.76, and 10.4 nM in LNCaP, VCaP, and 22Rv1 AR+ prostate cancer cell lines, respectively. ARD-69 is capable of reducing the AR protein level by >95% in these prostate cancer cell lines and effectively suppressing AR-regulated gene expression. |
| CSN26635 | ARCC-4 | 1973403-00-7 | ARCC-4 is a PROTAC, acting as an androgen receptor degrader. ARCC-4 is a low-nanomolar androgen receptor degrader able to degrade about 95% of cellular androgen receptors. ARCC-4 inhibits prostate tumor cell proliferation, degrades clinically relevant androgen receptor point mutants and unlike enzalutamide, retains antiproliferative effect in a high androgen environment. Thus, ARCC-4 exemplifies how protein degradation can address the drug resistance hurdles of enzalutamide. |
| CSN20433 | Androgen Receptor Modulator C7 | 2109805-69-6 | Androgen receptor modulator C7 is a potent AR ARE EC50 034 nM and tissue-selective NC interaction EC50 1206 nM modulator |
| CSN19392 | 3,3'-Diindolylmethane | 1968-05-4 | 3,3-Diindolylmethane is an AR structurally similar androgen receptor antagonist. |
| CSN39351 | Cyprodinil | 121552-61-2 | |
| CSN81050 | Cyprodinil-13C6 | 1773496-63-1 |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
